GlassScriptPhysician profile
Jaime Titus
NPI 1457928830
$5,387.89
in general payments reported to CMS, 2019-2025
29 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $1,062 · 2023: $868 · 2024: $1,099 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,052.45 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $500.26 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $386.46 | 2021-2025 | Trintellix |
| Abbvie INC. | $358.31 | 2022-2025 | |
| Alkermes, INC. | $356.05 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $269.14 | 2021-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $267.35 | 2024-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $254.43 | 2022-2024 | Jornay Pm |
| Corium, LLC | $236.06 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $185.20 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $152.20 | 2021-2022 | |
| Tris Pharma INC | $139.68 | 2021-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $137.36 | 2024-2025 | Uzedy |
| Supernus Pharmaceuticals, INC. | $134.34 | 2022-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $121.66 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $119.11 | 2022-2025 | Equetro, Equetro |
| Almatica Pharma LLC | $118.27 | 2021-2025 | Loreev Xr |
| Bausch Health US, LLC | $111.44 | 2022-2024 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $86.09 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $69.11 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $65.51 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $57.67 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $56.45 | 2023-2025 | Auvelity, Sunosi |
| Biogen, INC. | $48.34 | 2021-2022 | |
| Sage Therapeutics, LLC | $37.02 | 2025 | Zurzuvae |
| Luye Pharma (USA) LTD. | $18.60 | 2025 | Erzofri Extended-Release |
| Vertical Pharmaceuticals, LLC | $17.58 | 2024 | Relexxii |
| Harmony Biosciences LLC | $17.27 | 2021 | |
| Noven Therapeutics, LLC | $14.48 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Titus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.